Small Pharma's (CVE:DMT) Peter Rands joins Proactive to introduce his company after launching on Toronto’s TSX Venture Exchange, raising C$58mln to develop medicines based on N,N-Dimethyltryptamine (DMT) to treat depression.
The firm is committed to helping accelerate the development of effective therapeutic treatments for mental health disorders.
The company is currently conducting the world’s first clinical trials exploring the potential for the psychedelic N, N-Dimethyltryptamine (DMT) combined with psychotherapy as a treatment for depression.